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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S84Wilcoxon single-rank test, or Mann-Whitney's U-test were employed
for the statistical analysis and values of p < 0.05 were considered
signiﬁcant.
Results: Before ACL-R, average volume of synovial ﬂuid was 7.6+/-7.2ml
although it varied from individual patient (Max 15.5ml, Min 0.5ml). In
all patients, synovial ﬂuid volume surged around 3-fold at day 3 post
surgery (average 21.6+/-8.0ml, Max 25ml, Min 7.8ml). In most patients,
synovial ﬂuid volume returned to the basal level within 3 weeks post
surgery. Concentrations of TNF-alpha and IL1-beta were signiﬁcantly
increased at day 3 post surgery if compared to those at pre-operation
(p<0.05). In addition, the concentration of TNF-alpha was positively
correlated with the volume of synovial ﬂuid at pre-operation (r¼0.995,
p<0.01) and day3 post-operation (r¼0.535, p<0.05) while IL1-beta
levels were not at any time point. Throughout the time point, BMP7
levels were very low and did not change signiﬁcantly at pre- and post-
operation. Surprisingly, BMP7 levels were positively correlated with
IL1-beta levels at day 3 post-operation (r¼0.59, p<0.01). These suggest
that BMP7 may have subtle anti-inﬂammatory/anti-catabolic effect on
cartilage at the acute inﬂammatory stage after joint injury.
Conclusion: This is a longitudinal study of dynamic analysis of cytokine
levels in synovial ﬂuid from each patient undergoing ACL-R. In this
report, we examined the levels of TNF-alpha, IL1-beta, and BMP7 in
synovial ﬂuid and observed that TNF-alpha levels were signiﬁcantly
correlated with the volume of synovial ﬂuid.Figure 2. Method to determine initial concentration of biomarker within the syno-
vial ﬂuid.142
BIOMARKERS TO IDENTIFY CARTILAGE DAMAGE ARE INCREASED
AFTER A JOINT BLEED; AN EXPLORATIVE HUMAN AND CANINE IN
VIVO STUDY
L.F. van Vulpen, M.E. van Meegeren, G. Roosendaal, S.C. Mastbergen, F.P.
Lafeber. UMC Utrecht, Utrecht, The Netherlands
Purpose: Biomarkers have the capacity to detect cartilage degradation
in degenerative joint diseases such as osteoarthritis. They have the
potential to detect early, pre-radiographic changes in joints. In hae-
mophilia, a disease accompanied with arthropathy due to spontaneous
bleedings in the joint, a panel of four biomarkers for cartilage degra-
dation is associated with overall radiographic joint damage (Jansen et
al., A&R 2009). In the present study, we investigated for the ﬁrst time
whether these biochemical markers can detect cartilage degradation
immediately after a joint bleed.
Methods: Urinary C-terminal telopeptide of type II collagen (CTX-II),
serum Cartilage Oligmeric Matrix Protein (COMP), serum C1,2C
(cleavage product of both collagen type I and type II), and serum CS846
(the 864 epitope of aggrecan chondroitin sulphate) were measured in
samples of patients with haemophilia (n¼8). Samples were collected at
three different time points: within 2 days, after 3-5 days, and about 90
days after the patient reported a joint bleed (the last time point
considered baseline). In parallel, the same biomarkers were measured
in an experimental joint bleeding model using 7 dogs at four different
time points: before they received an experimental joint bleed (induced
by intra-articular autologous blood injections over 5 days), immediately
after this bleeding episode, 5 and 90 days later.
Results: In haemophilia patients, the levels of all four biomarkers were
elevated 3-5 days after a joint bleed when compared to baseline levels,
although the increase was not statistically signiﬁcant for each of the
biomarkers individual. A combined score of the four biomarkers 3-5
days after the bleed showed a statistically signiﬁcant increase when
compared to levels directly after the bleed (ratio of 1.010.17 at day 1-2
to a ratio of 1.100.20 at day 5; p¼0.024).
In parallel, in dogs, 5 days after the experimentally induced joint bleed,
the same panel of biomarkers (except sCOMP) was increased; uCTX-II
and the combined biomarker score being statistically signiﬁcantly
different from the time point directly after the bleed (3.810.85 vs
2.601.41, p¼0.007 and a ratio of 1.170.42 compared to a ratio of
0.980.39; p¼0.02 respectively). After 90 days the levels were similar
to the pre-bleeding levels.
Conclusions: This study demonstrates that biochemical markers of
joint tissue damage increase after a single joint bleed, both in haemo-
philia patients and after an experimentally induced canine joint bleed.
Due to the great variation in patients and bleeding characteristics in
a small number of patients, these effects were only approaching
statistical signiﬁcance. A combined score could be used to detect
cartilage degradation immediately after a joint bleed.Irrespectively, this explorative study clearly warrants further research
on the value of biochemical markers to detect the destructive properties
of a joint bleed.
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MAGNETICCOLLECTIONOFJOINT-LEVELOSTEOARTHRITISBIOMARKERS
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Florida, Gainesville, FL, USA
Purpose: Osteoarthritis (OA) comprises a continuum of joint remod-
eling across several years. The initiating events of OA are often
unknown, and OA is not typically diagnosed until signiﬁcant joint
degeneration has occurred. Detection of early-stage OA may provide
a better therapeutic window for disease modifying OA drugs, and the
OA research community has placed an emphasis on the development of
molecular OA biomarkers with the potential to detect OA prior to
radiographic evidence of joint destruction. The purpose of this study is
to describe a new magnetic nanoparticle-based technology for the
extraction of molecular biomarkers from an OA-affected joint (Figure 1).
Methods: In the magnetic collection technique, magnetic particles
functionalized with an antibody to a speciﬁc OA biomarker are injected
into the joint. Following an incubation period, a magnetic micro-needle
is inserted into the joint space, collecting a portion of the particle-
biomarker conjugates. Finally, the probe is removed, and biomarkers
and particles are processed for analysis. To determine the concentration
of biomarker within the joint, the amount of antibody and biomarker
collected with the magnetic needle must be quantiﬁed. As long as the
antibody-conjugated particles do not signiﬁcantly deplete the
biomarker within a joint, the law of mass action can be applied to
determine the joint-level biomarker concentration (Figure 2).
As a proof of concept, antibodies to the collagen degradation product
CTX-II were conjugated to horseradish peroxidase (HRP) and covalently
attached to 1 mm magnetic particles using an EDC crosslinking agent.
These particles were mixed with bovine synovial ﬂuid and allowed to
bind CTX-II for 5min. After incubation, particles were collected from the
synovial ﬂuid using an NdFeB micro-needle. The remaining ﬂuid and
uncollected particles were separated using a magnetic plate. Harvested
particles were diluted in 35 mL PBS containing 0.05% TWEEN-20, 2% BSA,
and 2 mM EDTA. 1 mL of sample were used for HRP analysis, with the
remaining 34 mL of sample heated at 85C for 3 min to release CTX-II.
Control experiments demonstrated brief heating completely disrupts
the interaction of biomarker and antibody, but did not signiﬁcantly
affect the level of detectable biomarker (not shown). Samples were
cooled to room temperature and centrifuged at 18,000g for 10 min.
Supernatants were analyzed for CTXII using Serum Pre-Clinical Carti-
Laps ELISA kit.
